Pattern of malignant disorders in individuals with Down's syndrome

Lancet Oncology

Volumn 2, Issue 7, 2001, Pages 429-436

  Hasle, Henrik ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHROMOSOME 21; DOWN SYNDROME; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFANT; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASM; NEWBORN; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0035412104     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00435-6     Document Type: Review

References (51)

1. Krivit W., Good R.A. Simultaneous occurrence of mongolism and leukemia. Am J Dis Child. 94:1957;289-298.
2. Narod S.A., Stiller C.A., Lenoir G.M. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 63:1991;993-999.
3. Satgé D., Sasco A.J., Carlsen N.L.T., et al. A lack of neuroblastoma in Down's syndrome: a study from 11 European countries. Cancer Res. 58:1998;448-452.
4. Olson J.M., Hamilton A., Breslow N.E. Non-11p constitutional chromosome abnormalities in Wilms' tumor patients. Med Pediatr Oncol. 24:1995;305-309.
5. Scholl T., Stein Z., Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol. 24:1982;817-829.
6. Satgé D., Sommelet D., Geneix A., et al. A tumoral profile in Down's syndrome. Am J Med Genet. 78:1998;207-216.
7. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 355:2000;165-169.
8. Nishi M., Miyake H., Takeda T., Hatae Y. Congenital malformations and childhood cancer. Med Pediatr Oncol. 34:2000;250-254.
9. Hasle H., Kerndrup G., Jacobsen B.B. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia. 9:1995;1569-1572.
10. Robison L.L., Nesbit M.E.J., Sather H.N., et al. Down's syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr. 105:1984;235-242.
11. Zipursky A., Thorner P., De Harven E., et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 18:1994;163-171.
12. Lie S.O., Jonmundsson G., Mellander L., et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 94:1996;82-88.
13. Lange B.J., Kobrinsky N., Barnard D.R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome: Children's cancer group studies 2861 and 2891. Blood. 91:1998;608-615.
14. Slørdahl S.H., Smeland E.B., Holte H., et al. Leukemic blasts with markers of four cell lineages in Down's syndrome ("Megakaryoblastic leukemia"). Med Pediatr Oncol. 21:1993;254-258.
15. Hasle H., Wadsworth L.D., Massing B.G., et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 106:1999;1027-1032.
16. Zipursky A., Brown E., Christensen H., et al. Leukemia and/or myeloproliferative syndrome in neonates with Down's syndrome. Semin Perinatol. 21:1997;97-101.
17. Homans A.C., Verissimo A.M., Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 15:1993;392-399.
18. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 110:2000;512-524.
19. Miller R.W., Shurin S.B. Neonatal myeloproliferative disorder in Down's syndrome: transient or preleukemic? Proc Am Soc Ped Hem/Oncol. 3:1994;24.
20. Crombet O., Svarch E. Down's syndrome and juvenile myelomonocytic leukemia. Pediatr Hematol Oncol. 16:1999;181-182.
21. Kojima S., Sako M., Kato K., et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 14:2000;786-791.
22. Creutzig U., Ritter J., Vormoor J., et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia. 10:1996;1677-1686.
23. Craze J.L., Harrison G., Wheatley K., et al. Improved survival of acute myeloid leukaemia in Down's syndrome. Arch Dis Child. 81:1999;32-37.
24. Zipursky A., Wang H., Brown E.J., Squire J. Interphase cytogenetic analysis of in vivo differentiation in the myelodysplasia of Down's syndrome. Blood. 84:1994;2278-2282.
25. Sato A., Imaizumi M., Koizumi Y., et al. Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21q. Br J Haematol. 96:1997;614-616.
26. Ravindranath Y., Abella E., Krischer J.P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 80:1992;2210-2214.
27. Taub J.W., Huang X., Matherly L.H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down's syndrome and non-Down's syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 94:1999;1393-1400.
28. Pui C.H., Raimondi S.C., Borowitz M.J., et al. Immunophenotypes and karyotypes of leukemic cells in children with Down's syndrome and acute lymphoblastic leukemia. J Clin Oncol. 11:1993;1361-1367.
29. Dördelmann M., Schappe M., Reiter A., et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Leukemia. 12:1998;645-651.
30. Lanza C., Volpe G., Basso G., et al. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down's syndrome. Leukemia. 11:1997;820-821.
31. Kaleem Z., Shuster J.J., Carroll A.J., et al. Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): a Pediatric Oncology Group Study. Leukemia. 14:2000;238-240.
32. Belkov V.M., Krynetski E.Y., Schuetz J.D., et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 93:1999;1643-1650.
33. Stiller C.A., Eatock E.M. Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child. 81:1999;202-208.
34. Seghezzi L., Dellavecchia C., Maserati E., et al. Ph-positive CML in blastic phase with monosomy 7 in a Down's syndrome patient. Monitoring by interphase cytogenetics and demonstration of maternal allelic loss. Cancer Genet Cytogenet. 99:1997;77-80.
35. Iselius L., Jacobs P., Morton N. Leukaemia and transient leukaemia in Down's syndrome. Hum Genet. 85:1990;477-485.
36. Okuda T., Cai Z., Yang S., et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 91:1998;3134-3143.
37. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 23:1999;166-175.
38. Fabia J., Drolette M. Malformations and leukemia in children with Down's syndrome. Pediatrics. 45:1970;60-70.
39. Sandoval C., Hudson M.M., Ozkaynak M.F., et al. Down's syndrome and Hodgkin disease in childhood. Med Pediatr Oncol. 34:2000;304-305.
40. Satgé D., Sasco A.J., Cure H., et al. An excess of testicular germ cell tumors in Down's syndrome: three case reports and a review of the literature. Cancer. 80:1997;929-935.
41. Hasle H., Mellemgaard A., Nielsen J., Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer. 71:1995;416-420.
42. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 378:1995;776-779.
43. Mitelman F., Heim S., Mandahl N. Trisomy 21 in neoplastic cells. Am J Med Genet Suppl. 7:1990;262-266.
44. Yamamoto N., Uzawa K., Miya T., et al. Frequent allelic loss/imbalance on the long arm of chromosome 21 in oral cancer: evidence for three discrete tumor suppressor gene loci. Oncol Rep. 6:1999;1223-1227.
45. Ohgaki K., Iida A., Kasumi F., et al. Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers. Genes Chromosomes Cancer. 23:1998;244-247.
46. De La Torre R., Casado A., Lopez-Fernández E., et al. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia. 52:1996;871-873.
47. Slavc I., Urban C., Haas O.A., et al. Acute megakaryocytic leukemia in children. Clinical, immunologic, and cytogenetic findings in two patients. Cancer. 68:1991;2266-2272.
48. Zagzag D., Miller D.C., Cangiarella J., et al. Brainstem glioma after radiation therapy for acute myeloblastic leukemia in a child with Down's syndrome. Possible pathogenetic mechanisms. Cancer. 70:1992;1188-1193.
49. Sørensen S.A., Fenger K., Olsen J.H. Significant lower incidence of cancer among patients with Huntington disease. An apoptotic affect of an expanded polygutamine tract? Cancer. 86:1999;1342-1346.
50. Gurney J.G., Severson R.K., Davis S., Robison L.L. Incidence of cancer in children in the United States. Sex-, race, and 1-year age-specific rates by histologic type. Cancer. 75:1995;2186-2195.
51. Hattori M., Fujiyama A., Taylor T.D., et al. The DNA sequence of chromosome 21. Nature. 405:2000;311-319.